作者 Roger McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology, University of Toronto, Toronto, Canada
Chairman and Executive Director, Brain and Cognition Discovery Foundation (BCDF), Toronto, Canada
Director, Depression and Bipolar Support Alliance (DBSA), Chicago, IL; USA
Mansur RB, Lee Y, Zhou AJ, et al. Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. Ann Clin Psychiatry. 2018;30(1):38-50.
Lee Y, Smofsky A, Nykoliation P, et al. Cognitive impairment mediates workplace impairment in adults with type 2 diabetes mellitus: Results from the Motivaction study. Can J Diabetes. 2018;42(3):289-95.
Baskaran A, Milev R, McIntyre RS. A review of electroencephalographic changes in diabetes in relation to major depressive disorder. Neuropsychiatr Dis Treat. 2013;9:143-50.
McIntyre RS, Mansur RB, Lee Y, et al. Adverse effects of obesity on cognitive function in individuals at ultra high risk for bipolar disorder: Results from the global mood and brain science initiative. Bipolar Disord. 2017;19(2):128-34.
Kleinridders A, Cai W, Cappellucci L, et al. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci USA. 2015;112(11):3463-8.
Zhang H, Hao Y, Manor B, et al. Intranasal insulin enhanced resting-state functional connectivity of hippocampal regions in type 2 diabetes. Diabetes. 2015;64(3):1025-34.
McIntyre RS, Soczynska JK, Woldeyohannes HO, et al. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. Bipolar Disord. 2012;14(7):697-706.
Mansur RB, Ahmed J, Cha DS, et al. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study. J Affect Disord. 2017;207:114-20.
Unpublished data.
Present disclosure: The presenter reported that he has received research and/or grants from Stanley Medical Research Institute, CIHR. China National Natural Research Foundation, Lundbeck, and Shire. In the past 2 years, he has received fees for speaking/consultation from Shire, Purdue, Otuska, Janssen-Ortho, Lundbeck, Pfizer, Neurocrine, Neuralstem, Sunovion, Takeda, and Allergan.